Form 4: Enliven Therapeutics Director Richard A. Heyman Reports Stock Sales

Director Richard A. Heyman reported the sale of Enliven Therapeutics (ELVN) stock on October 18, 2024, according to a Form 4 filing with the SEC.

Summary

• Richard A. Heyman, a director of Enliven Therapeutics, Inc. (ELVN), reported the sale of company stock on October 18, 2024.
• The sales were executed under Rule 10b5-1 trading plans adopted on July 17, 2023.
• A total of 817 shares were sold directly at a weighted average price of $30.003, and 753 shares were sold indirectly at a weighted average price of $30.0021.
• Following the transactions, Heyman directly owns 123,673 shares and indirectly owns 27,165 shares through RAHD Capital LLC and 37,407 shares through the Richard A. Heyman and Anne E. Daigle Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of stock sales by a company director. The sales were pre-planned under a Rule 10b5-1 trading plan, which mitigates concerns about insider information.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, such as directors and officers, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's valuation and future prospects. Sales by insiders can sometimes be interpreted negatively, but often they are part of pre-planned diversification strategies.

Stakeholder Impact

• Shareholders may interpret the stock sale as a lack of confidence by the director, although the pre-planned nature of the sales mitigates this concern.

Key Dates